A targeted radiotherapy/gene therapy approach for prostate cancer, using the radiopharmaceutical [ 
Introduction
Prostate cancer is a disease of increasing importance in a rising elderly population. It is the most common cancer in men after skin cancer, and it is the second highest cause of cancer death after lung cancer in the USA. 1 Management of prostate cancer depends on grade and stage of the tumour, and on age and general health of the patient. Radiotherapy is one of the treatment modalities, which is an alternative to radical surgery (radical prostatectomy), for the treatment of locally confined disease (T1-2, N0, M0) either as external beam radiation (traditionally in the form of 'conventional external-beam radiotherapy' or more recently three-dimensional conformal radiotherapy) or as interstitial brachytherapy. 2, 3 Radiotherapy is also used for locally advanced disease, alone or in combination with hormonal therapy, or as adjuvant therapy after radical prostatectomy with positive margins. Relapse rate after radiotherapy is inversely related to the administered dose of radiation, but this is limited by the radiation toxicity to neighbouring organs. 2, 4 Tumour-specific radiotherapy would limit toxicity to neighbouring tissues, but increase radiation to tumour and consequently decrease relapse rate. Targeted radiotherapy uses a radionuclide combined with a tumourseeking drug. This allows the selective irradiation of tumour cells with sparing of normal tissue. Therefore, targeted radiotherapy is a possible alternative form of radiation treatment of prostate cancer.
One of the most promising tumour-selective radiopharmaceuticals is [ 131 I]meta-iodobenzylguanidine ([  131 I ]MIBG), a stable, nonimmunogenic analogue of adrenergic neurone blockers. This agent is used for the treatment of neural crest derived tumours. [5] [6] [7] These neuroendocrine tumours naturally express the membrane-bound noradrenaline transporter (NAT), enabling them to actively take up [ 131 I]MIBG, resulting in specific irradiation of the target tumour cells. Previously, we have demonstrated that plasmid-mediated transfection of the NAT gene into glioma cells, which do not endogenously possess NAT, leads to expression of a functional transporter, demonstrating the potential application of [ 131 I]MIBG therapy for malignancies other than neuroendocrine tumours. [8] [9] [10] One means of limiting the expression of the NAT transgene to tumour cells is by placing the transgene under the control of a tumour-specific promoter, such as telomerase. 11, 12 This is an especially attractive component of gene therapy of prostate cancer since there is increased expression of both the RNA component, human telomerase RNA (hTR), and the protein component, human telomerase reverse transcriptase (hTERT) in cancer cells, including prostate cancer, with little expression in normal cells. [13] [14] [15] [16] [17] [18] We demonstrate that a targeted tumour-specific radiotherapy/gene therapy strategy with [ 131 I]MIBG for prostate cancer is feasible and could be a promising option for future treatment of prostate cancer.
Materials and methods

Plasmids
Dr Michael Bruss and Professor Heinz Bonisch (University of Bonn, Germany) kindly donated bovine NAT cDNA.
Recombinant plasmids containing the bovine NAT cDNA (bNAT) under the control of one of three promoters, the universal viral CMV, the hTR, or the hTERT promoter, were constructed as previously described. 8, 11 The NAT cDNA fragment was subcloned into the promoterless pEGFP-1 plasmid (Clontech, BD Biosciences, Cowley, Oxford, UK) from which the EGFP gene had been removed. The promoter fragments were then subcloned into the multiple cloning site of the bNATcontaining promoterless plasmid. Plasmids contain a geneticin-resistance gene. Plasmid purification was carried out using Plasmid Maxi Kit (Qiagen Ltd., UK and Ireland, Crawley, West Sussex, UK).
Target cell lines
Two adenocarcinoma of prostate cell lines were used for these studies: LNCaP, an androgen-sensitive, PSA producing, human Caucasian adenocarcinoma line from lymph node metastases; and DU145, an androgeninsensitive, non-PSA producing, human adenocarcinoma line from cerebral metastases.
Culture conditions
DU145 cells were maintained in RPMI Glutamax-I (Gibco/Invitrogen Life Technology, Paisley, UK), supplemented with foetal bovine serum (10%, v/v), fungizone (2 mg/ml), and penicillin/streptomycin (100 U/ml).
LNCaP were maintained in RPMI 1640 with L-glutamine (Gibco/Invitrogen Life Technology, Paisley, UK), adding foetal bovine serum (10%, v/v), HEPES buffer (10 mM), sodium pyruvate (1 mM), glucose (2.25 g/l), fungizone (2 mg/ml), penicillin/streptomycin (100 U/ml).
Cells were cultured at 371C in a 5% CO 2 atmosphere and were regularly checked for mycoplasma infection.
Radiosensitivity to external beam irradiation
Survival of DU145 and LNCaP clonogens was determined after treatment with external beam irradiation delivered by a cobalt irradiator (Alycon II Teletherapy Unit). DU145 and LNCaP cells were plated at 7. . Cells were equilibrated with 5% carbon dioxide and incubated at 371C. After 16 days (DU145) and 21 days (LNCaP), the medium was removed and the colonies were fixed and stained with a 10% crystal violet solution. Colonies of more than 50 cells were scored.
To assess the contribution of b-particle crossfire to cell kill, clonogenic assays were also performed in the threedimensional spheroid model. 9, 22 Aliquots of spheroids were transferred to 20 ml universal containers and suspended in 1 ml of medium containing [
131 I]MIBG at doses ranging from 0 to 10 MBq/ml. These were incubated with agitation for 2 h at 371C. Spheroids were washed twice with PBS before addition of 5 ml of fresh medium and incubated at 371C in a 5% CO 2 atmosphere for 48 h to allow absorption of b-decay energy by neighbouring nontransfected cells. 9 After 48 h, spheroids were washed twice with PBS, incubated with 1 ml of trypsin for 10 min, and manually disaggregated using a 5 ml pipette. For clonogenic assay, cells were counted and plated at appropriate concentrations in 25 cm 2 flasks.
Statistical analysis
Statistical analysis of results was performed using a MINITAB statistical package. Paired t-tests were performed to determine whether the differences in the mean uptake between the DMI inhibited controls and the non-DMI inhibited transfectants were statistically significant. For clonogenic assay results, two-sample t-tests were performed to assess the statistical significance of the differences in mean SF between the parental, nontransfected cells and the transfectants expressing NAT.
Results
Surviving fraction of DU145 and LNCaP cells after c-irradiation
The surviving fraction (SF) at 2 Gy showed DU145 and LNCaP adenocarcinoma of prostate cell lines to be moderately radiosensitive. LNCaP was more radiosensitive than DU145: SF at 2 Gy (SF 2 ) was 0.67 for DU145, and 0.31 for LNCaP (Figure 1 ).
To assess the expression of the NAT transgene in the transfectants, [ 131 I]MIBG uptake was measured in the LNCaP and DU145 cells transfected with the recombinant plasmids containing the NAT cDNA under the control of either the CMV, hTR or hTERT promoters. Targeted radiotherapy/gene therapy NE Fullerton et al fected with the NAT gene under the control of the hTERT and hTR promoter showed an 8-and 6.5-fold enhancement, respectively, of active uptake. The level of uptake achieved in the LNCaP transfectants compared favourably with that of SK-N-BE(2c) neuroblastoma cells which endogenously express the NAT gene. 11, 23 In the NATtransfected cells, the differences in uptake between the DMI inhibited controls and the non-DMI inhibited samples were statistically significant (Po0.05 for LNCaP-hTERT/NAT; Po0.005 for DU145-hTR/NAT; Po0.001 for LNCaP-CMV/NAT, LNCaP-hTR/NAT, DU145-CMV/NAT and DU145-hTERT/NAT).
These results demonstrate that transfection of the NAT transgene into prostate cancer cells under the control of the CMV, hTR or hTERT promoter resulted in expression of a functional NAT.
Active uptake was dependent on cell density. At cell densities greater than 60-70% confluence, cell growth was no longer in exponential phase and active uptake of [ 131 I]MIBG decreased relative to that observed at densities less than 60-70% confluence (Figures 4 and 5) .
Dose-dependent toxicity of [
131 I]MIBG to DU145
and LNCaP parental cells and transfectants expressing NAT
Clonogenic assays were performed to determine whether uptake of [ 131 I]MIBG translated into dose-dependent cell kill in two-dimensional monolayers and in three-dimensional spheroids. 9, 22 As illustrated in Figures 6a and 7a NAT-transfected clonogens was observed compared to those derived from LnCaP transfectants. This is consistent with the comparative uptake capacities of these cells (Figures 2 and 3) . Effective sterilisation of LNCaP transfectants expressing NAT was observed at 10 MBq. SF at 10 MBq/ml was 0.58 for LNCaP; 0.02 for LNCaP-CMV/NAT; 0.04 for LNCaP-hTERT/NAT; 0.01 for LNCaP-hTR/NAT; 0.86 for DU145; 0.15 for DU145-CMV/NAT; 0.33 for DU145-hTERT/NAT; 0.31 for DU145-hTR/NAT ( Table 1 ).
The differences in SF between the parental cells and the NAT-transfected cells at all radioactivity doses were statistically significant (Po0.001) for both LNCaP and DU145 cell lines.
These cell kill data showed a relationship between [ 131 I]MIBG uptake and cell kill in NAT transfected prostate cancer cells.
The spheroid model was used to assess the contribution of the bystander effect to cell kill (Figures 6b and 7b) . A dose-dependent reduction in SF was observed for cells from disaggregated spheroids comprised of NAT transfected cells. At 7.5 MBq, LNCaP and DU145 transfectants expressing NAT were sterilised. SF at 10 MBq/ml was 0.49 for LNCaP; 0.0 for LNCaP-CMV/NAT; 0.01 for The lower SF observed in spheroid clonogenic assays, as compared to monolayer experiments, is consistent with a contribution of dose-dependent radiation crossfire to cell kill in this three-dimensional culture.
The substantial sterilisation achieved after treatment with 7.5 MBq/ml of [
131 I]MIBG of DU145 NAT transfectants grown as spheroids, compared with DU145 NAT transfectants grown as monolayers, suggests a significant contribution from radiological bystander effects to toxicity.
Discussion
The treatment of prostate cancer is still a challenge. Many patients present with advanced disease and 20-40% of patients may eventually relapse after primary 'curative' Targeted radiotherapy/gene therapy NE Fullerton et al therapy. Adenocarcinoma of prostate is radiosensitive, but the dose of radiation that can be administered with current regimens is limited by normal tissue toxicity. The need for new developments in the treatment of prostate cancer has been recognized and research is now focusing on the potential of gene therapy. [24] [25] [26] Prostate cancer is an attractive target for gene therapy, because of the ease of access via transperineal, transrectal or transurethral routes. 25, 26 A new treatment strategy, combining a novel gene therapy approach with a well-established treatment option for prostate cancer-radiotherapy-might render radiation treatment more effective and more readily tolerated. Targeted radiotherapy with meta- In order to achieve tumour-specificity, the expression of the NAT transgene must be limited to malignant cells by placing its transcription under the control of a tumour-specific element, such as a telomerase promoter. Telomere length is maintained in malignant cells by activation of the reverse transcriptase enzyme, telomerase. Upregulation of telomerase is an important factor in the immortalisation of cancer cells. [27] [28] [29] Therefore, telomerase is a suitable promoter to achieve tumourspecificity of transgene expression due to the difference in telomerase expression between normal and malignant cells. Indeed, previous in vitro studies have already identified telomerase as a potent tumour-specific promoter, 11, 12, 30 and 80-90% of adenocarcinoma prostate cells, regardless of stage, are telomerase-positive. [13] [14] [15] [16] [17] [18] Both the human telomerase RNA (hTR) and the human telomerase reverse transcriptase (hTERT) promoters compared favourably with the strong ubiquitous CMV promoter with respect to their ability to drive the expression of the NAT transgene. In transfected LNCaP cells, the uptake achieved by NAT under the control of the telomerase promoters was similar to that achieved by the neuroblastoma cell line SK-N-BE(2c) which endogenously expresses NAT. 23 No significant difference was observed between the uptake and cell kill achieved by LNCaP and DU145 NAT transfected cells under the control of either the hTR or the hTERT promoter. It has previously been shown that the hTR gene is expressed at high levels in cancer cells, yet can also be detected at low levels in some normal tissues, while the hTERT gene is expressed at lower levels in cancer cells and is generally undetectable in normal cells. 12 This suggests that both promoters may be of use for genetic therapies designed to target genes to malignant cells via tumour-specific gene expression.
The tissue-specific promoter, PSA, could also be used to restrict the effects of targeted radiotherapy to prostate cancer cells. 31, 32 However, it has previously been shown in our department that LNCaP cells transfected with the NAT gene under the control of the PSA rather than the telomerase promoter achieved less impressive uptake of
Furthermore the telomerase promoter, although it can be modulated by androgens, is not androgen-dependent for its function. 18 A future approach to achieve even higher prostate cancer specificity could involve a combination of telomerase and PSA promoters.
In the present study, a greater cell kill was achieved, for the same dose of [ 131 I]MIBG, in three-dimensional spheroids compared to monolayers, demonstrating the existence of collateral cell kill. This is of great importance to the success of gene therapy, since gene transmission is an inefficient process. That is, 100% transfection efficiency cannot be achieved using available methodology. Therefore, it is necessary to delineate the mechanism of induction of radiation-induced bystander effects in order to maximise the effectiveness of gene therapy used in conjunction with targeted radionuclide treatment.
Two types of bystander effect have been identified: namely a physical effect in the form of decay particle, crossfire irradiation from targeted cells to neighbouring, untargeted cells, observed mainly in conjunction with low linear energy transfer (LET) b-and g-emitters; and transmissible biological effects resulting from the radiation insult. The latter phenomenon is more pronounced following high LET radiation, such as a-particle irradiation. [33] [34] [35] For the MIBG-targeted radiotherapy of neuroectodermal tumours, the radionuclide conventionally utilised is 131 I. However, tumours of submillimetre dimensions are suboptimal targets for treatment with 131 I b-particles whose mean range is about 800 mm. 36 In addition to underdosing of small tumour deposits, long-range bemissions may damage surrounding normal tissues. [37] [38] [39] Owing to their short path length, radionuclides that decay by the emission of a-particles, such as the heavy halogen astatine-211 ( 211 At), offer the prospect of combining cell-specific molecular targeting with radiation having a range in tissue of only 50-80 mm. 40, 41 Moreover, a-particles are much more radiotoxic than bemitting radionuclides and their cytocidal efficiency is independent of cell cycle status and oxygen concentra- Because of the anatomical position of the prostate gland, prostate cancer is an attractive target for this novel treatment strategy which combines gene transfer and radionuclide therapy. Targeted radiotherapy could be delivered in a manner similar to the transperineal implantation of radioactive seeds in permanent interstitial brachytherapy. 3 In conclusion, we have demonstrated that transfection of NAT cDNA into human prostate cancer cells, under the control of a telomerase promoter, resulted in the expression of a functional transporter capable of active uptake of [ 131 I]MIBG and resulting in dose-dependent tumour cell kill.
This targeted gene-and radiotherapy approach could be an exciting new option for radiation treatment of prostate cancer.
